Ben Richardson, CEO at SulNOx, confident they can cost-effectively decarbonise commercial shipping. Watch the video here.
Up 17% games played dropping 3% on no trades
RNS…https://www.lse.co.uk/rns/PYC/physiomics-expands-technical-team-h1l32wy11dsuxxq.html
40k buy limits yesterday at the close.. due explosive move
Should go well today NT 5p at the close yesterday large bid again.. news on big pharma could drop any day ??
Just read the RNS’s work it out….Q: Please say a few words on the current pipeline?
The pipeline is genuinely the strongest it’s ever been. For the first time, we’ve really been able to quantify that by disclosing that we have contracted revenue of over £460,000 for this half that we’re in now. We’ve never been able to say that before. We’ve never had that degree of visibility for the next five months. And obviously that’s just the revenues that we have signed up at this point in time.
Above these contracted revenues in the pyramid of Business Development we have a number of contracts that are in discussion, one of which is with another big pharma Company. If we can clinch that one, that is another very exciting opportunity and could be a big step forward for the Company. But it’s not the only opportunity. We now have a more rigorous process for categorising the different opportunities thanks to our new BD lead. While this isn’t something that I can explain in a few words, I can assure you that at every stage within that BD funnel we now looking stronger than I think we ever have done before.
Something definately cooking behind the scenes. MMS will take 500k... Today options RNS... Added a few more today while its been quite :-)
PYC are helping Merck :-)
Biopharma giant Sanofi is setting its sights on AI for drug discovery, inking a deal worth more than $100 million with tech company Exscientia.
As part of the deal, Exscientia is eligible for as much as $5.2 billion in payments for clinical development, regulatory and commercial milestones.
More Merck deals coming As per Dec 2021 RNS
Merck have annualy increased their business with PYC and we are now a key partner for them as prove by the Dec 2021 RNS
MAR 2022 | DARMSTADT, GERMANY
Fiscal 2021
Group sales rise by 12.3% to € 19.7 billion; EBITDA pre up 17.3% to € 6.1 billion; EBITDA pre margin increases to 31.0%
Greater investments in high-growth businesses; net financial debt significantly lower
Earnings per share pre of € 8.72; proposed dividend rises by € 0.45 to all-time high of € 1.85
Yes, but since which we've now become integral to many of their drug pipeline as per May 2021 RNS
Additionally, Bicycle has developed a pharmacokinetic/pharmacodynamic (PK/PD) modelling framework intended to predict preclinical biomarker level and tumor growth inhibition in response to changes in the BT7480 dose and dosing schedule. Bicycle found that plasma and tumor drug concentration levels may be associated with tumor growth inhibition.
BT7480 was our 1st collaboration with them...and should produce royalties going foward
We also are moving our Bicycle TICA™? programs forward, including BT7480, which entered the clinic in the fourth quarter of 2021
March 1, 2022 at 7:00 AM EST
PDF Version
- Continued clinical progress across pipeline of Bicycle Toxin Conjugates®? (BTCs) and Bicycle tumor-targeted immune cell agonists (Bicycle TICAs)
- Cash of $438.7 million at December 31, 2021 expected to provide financial runway through 2024
Our original deal from 2018/19 was just BT7480 but reckon we are now involved in all such as the recent BT8009 above
Bicycle Therapeutics (NASDAQ: BCYC) is a clinical-stage biopharmaceutical company developing a novel class of medicines, referred to as Bicycles, for diseases that are underserved by existing therapeutics. Bicycles are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize their structural geometry. This constraint facilitates target binding with high affinity and selectivity, making Bicycles attractive candidates for drug development. Bicycle is evaluating BT5528, a second-generation Bicycle Toxin Conjugate (BTC™?) targeting EphA2; BT8009, a second-generation BTC targeting Nectin-4, a well-validated tumor antigen; and BT7480, a Bicycle TICA™? targeting Nectin-4 and agonizing CD137, in company-sponsored Phase I/II trials. In addition, BT1718, a BTC that targets MT1-MMP, is being investigated in an ongoing Phase I/IIa clinical trial sponsored by the Cancer Research UK Centre for Drug Development. Bicycle is headquartered in Cambridge, UK, with many key functions and members of its leadership team located in Lexington, Massachusetts
Completed over next 6mths...that means completed by Dec 2022
We have a high chance that we worked in this
21 May 2021
Physiomics plc
("Physiomics") or ("the Company")
Contract awards
Physiomics plc (AIM: PYC), the consultancy using mathematical models to support the development of drug treatment regimens and personalised medicine solutions, is pleased to announce that it has been awarded two further contracts by existing client Bicycle Therapeutics ("Bicycle") that it expects to be completed over the next six months. These projects relate to two of Bicycle's lead clinical assets and build on earlier work completed by Physiomics on these assets.
Physiomics CEO, Dr Jim Millen, commented: "We are delighted that Bicycle continues to commission new projects with us and believe that it demonstrates the strength and depth of the relationship we have developed with this key client."